Open Access Full Text Article

RETRACTION

MiR-502-3P Suppresses Cell Proliferation, Migration, and Invasion in Hepatocellular Carcinoma by Targeting SET [Retraction]

Jin H, Yu M, Lin Y, et al. *Onco Targets Ther*. 2016;9:3281—3289.

At the request of the authors, the Editor and Publisher of *OncoTargets and Therapy* wish to retract the published article. The journal was notified by the authors of potential issues relating to the reliability of the data in the published article. Specifically:

- Figure 2F panel 0 h Untreated shares overlap with a section of Figure 2F panel 0 h NC and panel 0 h Mimics.
- Figure 2F panel 24 h Untreated shares overlap with a section of Figure 2F panel 24 h NC.
- Table 1 describes the forward and reverse primers used for the miRNA has-MiR-502-3p. The forward and reverse primers are 50% identical and completely identical to the forward and reverse primers of the miRNA has-miR-144, respectively, described in Table 1 of Yu et al 'MiR-144 suppresses cell proliferation, migration, and invasion in hepatocellular carcinoma by targeting *SMAD4*' (https://doi.org/10.2147/OTT.S88233).

The authors explained that some of the images had been mislabelled which led to the duplication of images in Figure 2F. The authors explained the primers were designed using the poly A tail-length method and included universal sequences requiring specific changes according to the miRNA. This led to the similarities of the primers described in Table 1 to those described in Yu et al. In addition, the authors could not provide any raw data for the western blots shown in the article.

Given the errors and lack of available raw data the authors requested for the article to be retracted and the editor has agreed with this decision. The authors wish to apologise for this error.

Our decision-making was informed by our policy on publishing ethics and integrity and the COPE guidelines on retraction.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as "Retracted".

agents and protocols on patient perspectives such as quality of life,

adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/

testimonials.php to read real quotes from published authors.

OncoTargets and Therapy

Dovepress

Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic

Submit your manuscript here: https://www.dovepress.com/oncotargets-and-therapy-journal

https://doi.org/10.2147/OTT.S319075

Received: 7 May 2021 Accepted: 7 May 2021 Published: 18 May 2021

OncoTargets and Therapy 2021:14 3177

3177

© 2021 Dove Medical Press. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/ the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. for permission for commercial use of this work, please see paragraph 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).